Multiple Firms Compete to Lead Medpace Securities Suit After Lower Book‑to‑Bill Disclosure

Overview

• Plaintiffs filed Durbin v. Medpace in federal court alleging executives misled investors about backlog cancellations and overstated growth guidance during a class period from April 22, 2025 through February 9, 2026.
• The suits say Medpace’s February 9, 2026 release reported a fourth-quarter 2025 book‑to‑bill ratio of 1.04 versus prior guidance of 1.15, which plaintiffs say revealed higher cancellations and triggered a roughly 16% one‑day share drop.
• Multiple plaintiff firms including Rosen, Faruqi, Schall and DJS are soliciting investors now to move for lead‑plaintiff status under competing early‑June deadlines, commonly June 5 to June 8.
• No class has been certified yet, so investors can either seek lead‑plaintiff appointment to direct the case or remain absent class members and retain separate counsel if they wish to participate in any recovery.
• Book‑to‑bill compares new contract bookings to billed work for contract research companies, and persistent cancellations can quickly lower revenue outlooks, increase scrutiny of management guidance, and affect potential shareholder recoveries.